Publications en collaboration avec des chercheurs de Complejo Hospitalario de Toledo (115)

2024

  1. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723

  2. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology

  3. T-cell immune profile in blood of systemic mastocytosis: Association with disease features

    Allergy: European Journal of Allergy and Clinical Immunology

2023

  1. Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547

  2. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  3. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1347-1359

  4. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality

    The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919

  5. Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series

    Gastroenterologia y Hepatologia

  6. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020

  7. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Altered innate immune profile in blood of systemic mastocytosis patients

    Clinical and Translational Allergy, Vol. 12, Núm. 6

  2. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

    Cancers, Vol. 14, Núm. 10

  3. Design and Rationale for a Real-World Prospective, Multicenter Registry of Myocardial Revascularization Failure and Secondary Revascularization: The REVASEC Study

    Cardiovascular Revascularization Medicine, Vol. 40, pp. 50-56

  4. Early clinical outcomes after transaxillary versus transfemoral TAVI. Data from the Spanish TAVI registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 479-487

  5. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

    Blood, Vol. 139, Núm. 4, pp. 572-583

  6. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  7. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2039-2051

  8. Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features

    Clinical and Translational Allergy, Vol. 12, Núm. 3

  9. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  10. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024